AU2003249693A1 - PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF - Google Patents

PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF

Info

Publication number
AU2003249693A1
AU2003249693A1 AU2003249693A AU2003249693A AU2003249693A1 AU 2003249693 A1 AU2003249693 A1 AU 2003249693A1 AU 2003249693 A AU2003249693 A AU 2003249693A AU 2003249693 A AU2003249693 A AU 2003249693A AU 2003249693 A1 AU2003249693 A1 AU 2003249693A1
Authority
AU
Australia
Prior art keywords
hla
molecules
peptides presented
peptides
presented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003249693A
Other versions
AU2003249693A8 (en
Inventor
Janine Bilsborough
Thierry Boon-Falleur
Christophe Panichelli
Erwin Schultz
Catia Traversari
Pierre Van Der Bruggen
Yi Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/164,121 external-priority patent/US20030228308A1/en
Priority claimed from US10/164,078 external-priority patent/US7041502B2/en
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU2003249693A8 publication Critical patent/AU2003249693A8/en
Publication of AU2003249693A1 publication Critical patent/AU2003249693A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003249693A 2002-06-05 2003-06-04 PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF Abandoned AU2003249693A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/164,121 2002-06-05
US10/164,121 US20030228308A1 (en) 2002-06-05 2002-06-05 Isolated peptides which bind to HLA-Cw6 molecules and uses thereof
US10/164,078 US7041502B2 (en) 2002-06-05 2002-06-05 Isolated peptides which bind to HLA-B18 molecules and uses thereof
US10/164,078 2002-06-05
PCT/US2003/017641 WO2003104259A2 (en) 2002-06-05 2003-06-04 PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2003249693A8 AU2003249693A8 (en) 2003-12-22
AU2003249693A1 true AU2003249693A1 (en) 2003-12-22

Family

ID=29738933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003249693A Abandoned AU2003249693A1 (en) 2002-06-05 2003-06-04 PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF

Country Status (2)

Country Link
AU (1) AU2003249693A1 (en)
WO (1) WO2003104259A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004542A1 (en) * 1993-08-06 1995-02-16 Cytel Corporation Cloning and characterization of the complete mage-1 gene
US6245525B1 (en) * 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US7041502B2 (en) * 2002-06-05 2006-05-09 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B18 molecules and uses thereof

Also Published As

Publication number Publication date
WO2003104259A2 (en) 2003-12-18
AU2003249693A8 (en) 2003-12-22
WO2003104259A3 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU2003288304A1 (en) Novel molecules derived from noraporphine
AU2003207940A1 (en) Conformationally constrained c-backbone cyclic peptides
AU2003290563A1 (en) Leptin-related peptides
WO2004092197A8 (en) Amyloid-specific peptides and uses thereof
EP1572168A3 (en) Anti-infarction molecules
AU2002953223A0 (en) Novel therapeutic molecules and uses thereof
AU2003249693A1 (en) PEPTIDES PRESENTED BY HLA-B18 AND Cw16 MOLECULES, AND USES THEREOF
AU2003236374A1 (en) Atopic dermatitis-inducing proteins
AU2003202694A1 (en) Torero protein
AU2003235768A1 (en) Molecular trichogram
AU2003270055A1 (en) Neurotransmission-associated proteins
AU2003278718A1 (en) Stars-a muscle-specification-binding protein
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF
AU2003219732A1 (en) Oligomeric molecules and uses thereof
AUPS161602A0 (en) Novel molecules and uses therefor
AU2003276655A1 (en) Pi - conjugated molecules
AU2003300785A1 (en) Carbohydrate-associated proteins
AU2003231478A1 (en) Novel protein, its dna and use thereof
AU2003239717A1 (en) Card-4 molecules and uses thereof
AU2003220067A1 (en) Jade nucleic acids, proteins and uses thereof
AU2003236908A1 (en) Proteins
AU2003295760A1 (en) Organelle-associated proteins
AU2003254865A1 (en) Akt2-BINDING PROTEIN
AU2003263751A1 (en) Novel proteins and their uses
WO2005063292A8 (en) Heh4 molecules and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase